LaVoieHealthScience Blog

Biotech is Back to Work: JPM 2023 Week Wrap Up

JP Morgan Week wrapped up earlier this month with a flurry of new data, partnerships, investor meetings, and pharmaceutical interest. Here are the five key takeaways of the conference and what to expect as we come to the end the first month of the year:  

  1. Biotech is Back: The COVID-19 pandemic caused a downturn for the biotech sector as whole, but JP Morgan Week showed a strong turnout, proving interest in both the science and investor sides of the industry. Overall, the state of the industry is strong, but there has been a massive over correction since the upheaval it faced during the pandemic. While the overall economy is influencing the industry, a continued emphasis on value-based care will push the biotech sector through these uncertain times. Value-based care is concerned with providing patients a high value service at a fair price.

  1. The Value of In-Person Conferences: Everyone from scientists and CEOs to investors went to San Francisco to attend JP Morgan Week in-person this year, with many citing in-person meetings and presentations as a key reason behind their success. The conference was at approximately 70% attendance, compared to pre-COVID years. The general demeanor was that everyone was incredibly happy to be back.

  1. Smaller Biotechs Need to Pivot: The valuation of smaller biotechnology companies is down considerably compared to previous years, but that does not mean it is time to panic, it means it is time to pivot. Venture Capitalists will continue to invest, but startups working on similar technologies to larger competitors will have a harder time attracting investors. Experts are confident in the fact that there is ample cash in the industry; companies simply need to be smarter about obtaining it. While it used to be enough to host one financing event a year, companies now may need multiple, smaller financing events to build their company. The money is out there; you just have to look for it a little harder.

  1. Acquisitions are Out: As we look forward to the rest of 2023, it is evident that partnerships will take a vested interest over acquisitions. Acquisitions have yet to materialize because partnerships allow larger companies to invest in new science without the risk of acquiring an entire company.

  1. What’s Trending: There were a lot of buzzwords thrown out at #JPM23, but some topics were more widely discussed on social media than others. Based on the Harris Poll, a social media study conducted by Endpoints News, gene editing and artificial intelligence were the undeniable stars of JP Morgan Week this year. Medical and investment experts alike spent the majority of their time discussing, attending panels, and investing in these two areas.

Developing a communications strategy to engage your target stakeholders whether they are investors, business partners, media, KOLs, or patients is key to achieving your business goals. LaVoieHealthScience can help you establish a strategy through our LHS Immersion® process and execute on that strategy through monthly communications programming. Reach out to us at to learn more.

Subscribe to the LHS Newsletter

* indicates required

Featured Event

No Events

Recent Blog Posts

Supercharge Your IR and More with Strategic Social Media

Investor relations and social media - two seemingly unrelated entities that, when combined, form a powerful strategy for modern businesses. Much like classic pairings such as peanut butter and jelly, eggs and bacon, or peas and carrots, the fusion of investor...

Balancing Act in Health and Science, IR & Communications

Are there differences in managing communications and strategic communications/investor relations (IR) across all industries? Are the basic skills that you would apply to other industries transferable to health and science industries? The role of the Chief...